We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sundial Growers Inc. (SNDL) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Sundial Growers Inc. (SNDL - Free Report) closed at $0.82, marking a +0.23% move from the previous day. This move outpaced the S&P 500's daily loss of 0.54%.
Coming into today, shares of the company had lost 10.54% in the past month. In that same time, the Medical sector lost 3.77%, while the S&P 500 gained 3.05%.
SNDL will be looking to display strength as it nears its next earnings release. Our most recent consensus estimate is calling for quarterly revenue of $8 million, down 45.09% from the year-ago period.
SNDL's full-year Zacks Consensus Estimates are calling for earnings of -$0.08 per share and revenue of $65 million. These results would represent year-over-year changes of +69.23% and +24.93%, respectively.
It is also important to note the recent changes to analyst estimates for SNDL. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 366.67% lower. SNDL is currently sporting a Zacks Rank of #4 (Sell).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 213, putting it in the bottom 17% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sundial Growers Inc. (SNDL) Gains As Market Dips: What You Should Know
In the latest trading session, Sundial Growers Inc. (SNDL - Free Report) closed at $0.82, marking a +0.23% move from the previous day. This move outpaced the S&P 500's daily loss of 0.54%.
Coming into today, shares of the company had lost 10.54% in the past month. In that same time, the Medical sector lost 3.77%, while the S&P 500 gained 3.05%.
SNDL will be looking to display strength as it nears its next earnings release. Our most recent consensus estimate is calling for quarterly revenue of $8 million, down 45.09% from the year-ago period.
SNDL's full-year Zacks Consensus Estimates are calling for earnings of -$0.08 per share and revenue of $65 million. These results would represent year-over-year changes of +69.23% and +24.93%, respectively.
It is also important to note the recent changes to analyst estimates for SNDL. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 366.67% lower. SNDL is currently sporting a Zacks Rank of #4 (Sell).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 213, putting it in the bottom 17% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.